Recent Updates
Recently added Catalysts
PTHS Positive Sentiment Score: 60/100

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Wednesday, November 5, 2025 1 min read
Key Takeaway: Pelthos Therapeutics Inc. is set to report its third quarter 2025 financial results on November 13, 2025. The announcement includes a conference call scheduled for 8:00 a.m. Eastern Time, where management will discuss the quarter's performance. The results will be released prior to the call, allowing for a detailed analysis of the company's financial standing. Pelthos is focused on innovative therapeutic solutions for patients with unmet treatment needs, having launched its product ZELSUVMI, approved in 2024 for molluscum contagiosum.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pelthos Therapeutics is committed to addressing unmet patient needs.
  • The company has successfully brought its lead product ZELSUVMI to market.
  • Upcoming financial results may reflect positive company growth.

Full Press Release Details

DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.
Pelthos management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1740524&tp_key=723fef088c
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
pelthos@kwmcommunications.com

Frequently Asked Questions

When is Pelthos Therapeutics' conference call?

The conference call is scheduled for November 13, 2025, at 8:00 a.m. ET.

What will be discussed in the conference call?

The call will cover Pelthos' third-quarter financial results ending September 30, 2025.

How can I access the conference call?

You can access the call via webcast at the provided link.

What is Pelthos Therapeutics’ primary product?

Pelthos' lead product is ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum.

When was ZELSUVMI™ approved?

ZELSUVMI™ was approved by the FDA in 2024.

Tags: PTHS Viatris Investor Conferences Healthcare Pelthos Therapeutics ZELSUVMI financial results biopharmaceuticals
Last updated: Nov 5, 2025